(MDLZ) Mondelez International - Ratings and Ratios
Biscuits, Chocolates, Gums, Candies
EPS (Earnings per Share)
Revenue
Dividends
| Dividend Yield | 3.50% |
| Yield on Cost 5y | 3.70% |
| Yield CAGR 5y | 10.51% |
| Payout Consistency | 94.8% |
| Payout Ratio | 68.1% |
| Risk via 5d forecast | |
|---|---|
| Volatility | 20.3% |
| Value at Risk 5%th | 32.8% |
| Relative Tail Risk | -1.76% |
| Reward TTM | |
|---|---|
| Sharpe Ratio | -0.31 |
| Alpha | -10.65 |
| CAGR/Max DD | -0.16 |
| Character TTM | |
|---|---|
| Hurst Exponent | 0.494 |
| Beta | 0.086 |
| Beta Downside | -0.055 |
| Drawdowns 3y | |
|---|---|
| Max DD | 26.67% |
| Mean DD | 10.17% |
| Median DD | 9.01% |
Description: MDLZ Mondelez International December 03, 2025
Mondelez International (NASDAQ: MDLZ) is a global snack-food company that manufactures and markets biscuits, crackers, snack bars, chocolates, gums, candies, and powdered beverages across all major regions, serving a wide array of retail channels from supermarkets to e-commerce platforms.
Key performance indicators from the most recent fiscal year (FY 2023) show net sales of approximately $28.7 billion, a 3.2 % organic growth driven primarily by emerging-market expansion and price-inflation offsets, with an adjusted operating margin of 16.5 %-the highest in the company’s history. The firm’s “Snacking Made Right” strategy targets a 5-6 % CAGR in the high-growth “better-for-you” segment through brands such as CLIF Bar and Tate’s Bake Shop.
Sector-wide drivers that materially affect Mondelez include persistent inflationary pressure on commodity inputs (cocoa, wheat, dairy), shifting consumer preferences toward convenient, protein-rich snacks, and the acceleration of direct-to-consumer and digital sales channels, which now account for roughly 12 % of total revenue and are expected to double by 2026.
For a deeper, data-rich assessment of MDLZ’s valuation dynamics, you might explore the analytical tools available on ValueRay.
Piotroski VR‑10 (Strict, 0-10) 5.0
| Net Income (3.53b TTM) > 0 and > 6% of Revenue (6% = 2.26b TTM) |
| FCFTA 0.03 (>2.0%) and ΔFCFTA -1.92pp (YES ≥ +1.0pp, WARN ≥ +0.5pp) |
| NWC/Revenue -22.22% (prev -21.78%; Δ -0.45pp) (YES ≤20% & Δ≤-1pp; WARN ≤25% & Δ≤0 oder ≤40% & Δ≤-3pp) |
| CFO/TA 0.05 (>3.0%) and CFO 3.58b > Net Income 3.53b (YES >=105%, WARN >=100%) |
| Net Debt (20.57b) to EBITDA (5.60b) ratio: 3.67 <= 3.0 (WARN <= 3.5) |
| Current Ratio 0.61 (target 1.5–3.0; WARN 1.2–<1.5 or >3.0–5.0; CFO/TA gate active) |
| Outstanding Shares last Quarter (1.30b) change vs 12m ago -3.01% (target <= -2.0% for YES) |
| Gross Margin 31.05% (prev 38.77%; Δ -7.72pp) >=18% & Δ>=+0.5pp (WARN >=15% & Δ>=0) |
| Asset Turnover 52.45% (prev 50.08%; Δ 2.37pp) >=50% & Δ>=+2pp (WARN >=35% & Δ>=0) |
| Interest Coverage Ratio 9.76 (EBITDA TTM 5.60b / Interest Expense TTM 437.0m) >= 6 (WARN >= 3) |
Altman Z'' 1.87
| (A) -0.12 = (Total Current Assets 13.15b - Total Current Liabilities 21.51b) / Total Assets 71.36b |
| (B) 0.51 = Retained Earnings (Balance) 36.39b / Total Assets 71.36b |
| (C) 0.06 = EBIT TTM 4.26b / Avg Total Assets 71.77b |
| (D) 0.55 = Book Value of Equity 24.93b / Total Liabilities 45.13b |
| Total Rating: 1.87 = (6.56 * A) + (3.26 * B) + (6.72 * C) + (1.05 * D) |
ValueRay F-Score (Strict, 0-100) 63.69
| 1. Piotroski 5.0pt |
| 2. FCF Yield 2.52% |
| 3. FCF Margin 6.08% |
| 4. Debt/Equity 0.84 |
| 5. Debt/Ebitda 3.67 |
| 6. ROIC - WACC (= 2.96)% |
| 7. RoE 13.44% |
| 8. Rev. Trend 80.76% |
| 9. EPS Trend 5.60% |
What is the price of MDLZ shares?
Over the past week, the price has changed by -0.29%, over one month by -3.38%, over three months by -11.99% and over the past year by -5.97%.
Is MDLZ a buy, sell or hold?
- Strong Buy: 11
- Buy: 8
- Hold: 9
- Sell: 0
- Strong Sell: 0
What are the forecasts/targets for the MDLZ price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 68.4 | 25.2% |
| Analysts Target Price | 68.4 | 25.2% |
| ValueRay Target Price | 51.6 | -5.6% |
MDLZ Fundamental Data Overview December 24, 2025
P/E Trailing = 20.4173
P/E Forward = 17.301
P/S = 1.8668
P/B = 2.6865
P/EG = 5.015
Beta = 0.397
Revenue TTM = 37.65b USD
EBIT TTM = 4.26b USD
EBITDA TTM = 5.60b USD
Long Term Debt = 17.13b USD (from longTermDebt, last quarter)
Short Term Debt = 4.19b USD (from shortTermDebt, last quarter)
Debt = 21.93b USD (from shortLongTermDebtTotal, last quarter)
Net Debt = 20.57b USD (from netDebt column, last quarter)
Enterprise Value = 90.84b USD (70.27b + Debt 21.93b - CCE 1.37b)
Interest Coverage Ratio = 9.76 (Ebit TTM 4.26b / Interest Expense TTM 437.0m)
FCF Yield = 2.52% (FCF TTM 2.29b / Enterprise Value 90.84b)
FCF Margin = 6.08% (FCF TTM 2.29b / Revenue TTM 37.65b)
Net Margin = 9.38% (Net Income TTM 3.53b / Revenue TTM 37.65b)
Gross Margin = 31.05% ((Revenue TTM 37.65b - Cost of Revenue TTM 25.95b) / Revenue TTM)
Gross Margin QoQ = 26.81% (prev 32.69%)
Tobins Q-Ratio = 1.27 (Enterprise Value 90.84b / Total Assets 71.36b)
Interest Expense / Debt = 0.10% (Interest Expense 22.0m / Debt 21.93b)
Taxrate = 15.52% (137.0m / 883.0m)
NOPAT = 3.60b (EBIT 4.26b * (1 - 15.52%))
Current Ratio = 0.61 (Total Current Assets 13.15b / Total Current Liabilities 21.51b)
Debt / Equity = 0.84 (Debt 21.93b / totalStockholderEquity, last quarter 26.18b)
Debt / EBITDA = 3.67 (Net Debt 20.57b / EBITDA 5.60b)
Debt / FCF = 8.98 (Net Debt 20.57b / FCF TTM 2.29b)
Total Stockholder Equity = 26.27b (last 4 quarters mean from totalStockholderEquity)
RoA = 4.95% (Net Income 3.53b / Total Assets 71.36b)
RoE = 13.44% (Net Income TTM 3.53b / Total Stockholder Equity 26.27b)
RoCE = 9.82% (EBIT 4.26b / Capital Employed (Equity 26.27b + L.T.Debt 17.13b))
RoIC = 7.81% (NOPAT 3.60b / Invested Capital 46.15b)
WACC = 4.84% (E(70.27b)/V(92.21b) * Re(6.33%) + D(21.93b)/V(92.21b) * Rd(0.10%) * (1-Tc(0.16)))
Discount Rate = 6.33% (= CAPM, Blume Beta Adj.) -> floored to rf + 0.7*ERP = 8.05%
Shares Correlation 3-Years: -100.0 | Cagr: -2.24%
[DCF Debug] Terminal Value 77.88% ; FCFE base≈2.85b ; Y1≈2.78b ; Y5≈2.79b
Fair Price DCF = 38.41 (DCF Value 49.56b / Shares Outstanding 1.29b; 5y FCF grow -3.84% → 3.0% )
EPS Correlation: 5.60 | EPS CAGR: 0.37% | SUE: 0.0 | # QB: 0
Revenue Correlation: 80.76 | Revenue CAGR: 6.63% | SUE: 0.23 | # QB: 0
EPS next Quarter (2026-03-31): EPS=0.79 | Chg30d=-0.015 | Revisions Net=-2 | Analysts=13
EPS next Year (2026-12-31): EPS=3.15 | Chg30d=-0.016 | Revisions Net=-3 | Growth EPS=+8.7% | Growth Revenue=+3.9%
Additional Sources for MDLZ Stock
Tweets: X | Stocktwits
Fund Manager Positions: Dataroma | Stockcircle